Login / Signup

Observations with alpelisib in older patients (≥ 65 year of age) with breast cancer in a non-clinical trial setting.

Yahya AlmodallalJennifer G Le-RademacherKathryn D CookSiddhartha YadavAmrit B SinghMinji LeeLisa M LammertAminah Jatoi
Published in: Breast cancer research and treatment (2021)
Older patients might derive further benefit from alpelisib if the adverse event profile of this agent, particularly the hyperglycemia, were able to be better managed.
Keyphrases
  • clinical trial
  • phase ii
  • study protocol
  • double blind
  • emergency department
  • phase iii
  • adverse drug